TIDMEKF

RNS Number : 3552M

EKF Diagnostics Holdings PLC

14 September 2023

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Notice of Interim Results

&

Investor Presentation

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that the Company will announce its interim results for the six months ended 30 June 2023 ("H1 2023"), on Tuesday 26 September 2023.

Investor Presentation

Julian Baines, Executive Chair, and Steve Young, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 5.30 pm on Tuesday 26 September 2023. The presentation is open to all existing and potential investors.

Investors can sign up to Investor Meet Company for free and register for the presentation here:

https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

 
EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com 
Julian Baines, Executive Chair                              Tel: +44 (0)29 2071 0570 
 
Singer Capital Markets (Nominated Adviser &                 Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / George Tzimas / Oliver 
 Platts 
 
Walbrook PR Limited                   Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 
                                                                                 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is an AIM-listed global diagnostics business focussed on:

-- Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

-- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORUOUSROUUKAAR

(END) Dow Jones Newswires

September 14, 2023 02:00 ET (06:00 GMT)

EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more EKF Diagnostics Charts.
EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more EKF Diagnostics Charts.